Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors

Miguel A. Villalona-Calero1,*, John P. Diaz2, Wenrui Duan3, Zuanel Diaz2, Eric D. Schroeder2, Santiago Aparo2, Troy Gatcliffe2, Federico Albrecht2, Siddhartha Venkatappa2, Victor Guardiola2, Sara Garrido2, Muni Rubens2, Fernando DeZarraga2 and Hao Vuong4

Abstract

Background: Given the observed antitumor activity of immune‐checkpoint-inhibitors in patients with mismatch-repair deficient (MSI-H) tumors, we hypothesized that deficiency in homologous-recombination-repair (HRR) can also influence susceptibility.

Methods: Patients with disease progression on standard of care and for whom pembrolizumab had no FDA approved indication received pembrolizumab. Patients with MSI-H tumors were excluded. Objectives included immune‐related objective response rate (iORR), progression‐free survival (PFS) and 20‐weeks-PFS. Pembrolizumab was given every 3 weeks and scans performed every six. We evaluated a triple‐stain (FANCD2foci/DAPI/Ki67) functional assay of the Fanconi Anemia (FA) pathway: FATSI, in treated patients' archived tumors. The two‐stage sample size of 20/39 patients evaluated an expected iORR ≥20% in the whole population vs. the null hypothesis of an iORR ≤5%, based on an assumed iORR ≥40% in patients with functional FA deficiency, and < 10% in patients with intact HRR. An expansion cohort of MSI stable endometrial cancer (MS-EC) followed. Exploratory stool microbiome analyses in selected patients were performed.

Results: Fifty-two patients (45F,7M;50-evaluable) were enrolled. For the 39 in the two‐stage cohort, response evaluation showed 2CR,5PR,11SD,21PD (iORR:18%). FATSI tumor analyses showed 29 competent (+) and 10 deficient (−). 2PR,9SD,1NE occurred among the FATSI+ (iORR:7%) and 2CR,3PR,2SD,3PD among the FATSI (−) patients (iORR:50%). mPFS and 20w-PFS were 43 days and 21% in FATSI+, versus 202 days and 70% in FATSI(−) patients. One PR occurred in the MS-EC expansion cohort.

Conclusions: Pembrolizumab has meaningful antitumor activity in malignancies with no current FDA approved indications and FA functional deficiency. The results support further evaluation of FATSI as a discriminatory biomarker for population‐selected studies.

Keywords: FancD2, Homologous recombination, Immune checkpoint inhibitor, Biomarkers, DNA repair, Fanconi

Introduction

Among the barriers to the generalized applicability of immune checkpoint inhibition as a therapeutic strategy is the identification of patients who will derive the most benefit. Le et al. reported a seminal phase 2 study that eventually led to the Food and Drug Administration's
(FDA) approval of pembrolizumab for the treatment of patients with advanced mismatch repair deficient tumors (MMR-d) [1, 2]. The investigators studied 41 patients with progressive metastatic carcinoma [1]. For patients with MMR-d colorectal cancer, the immune-related objective response rate (iORR) and 20-weeks immune-related progression-free survival (PFS) rate were 40% (4/10 patients) and 78% (7/9 patients), respectively. For MMR-proficient colorectal cancer the iORR and 20-weeks PFS were 0% (0/18 patients) and 11% (2/18 patients), respectively. Retrospective expansion to 149 patients with 15 different tumor types confirmed an ORR of 39.6%, with a 7% complete RR [2] for MMR-d tumors. Moreover, a follow up phase 3, randomized trial among 307 patients with metastatic MSI-H–MMR-d tumors. Moreover, a targeted FA sequencing panel performed in 49 FATSI negative specimens identified 34 unique alterations.

Alterations of note included BRCA tumor mutations with high VAF and demonstrated loss of heterozygosity in two of the germline BRCA carriers; a RAD51c (c223_224insA p.Y75*) with high VAF in a breast cancer patient experiencing a long duration antitumor response which was also detected in subsequent germline testing (Invitae, San Francisco CA); and both an ATM c.6976–1 G > T, not present in the germline, and an ERCC4 missense mutation (P379S) in both germline and tumor, in a lung carcinoma patient with tracheal infiltration experiencing massive hemoptysis after his first and only cycle of veliparib [20]. Tumors and adjacent tissue from 10 patients FATSI-positive per screening were analyzed as controls with the FA sequencing panel. A deleterious mutation (ERCC4), along with a germline potentially damaging mutation in FAN1, was found in only one patient.

We hypothesized that FATSI staining, given its ability to differentiate between functionally deficient and functionally competent FA pathway tumors, could identify additional patients susceptible to pembrolizumab for which no FDA approved indications exist. Rather than patient pre-selection, a design that incorporates all comers with a post-hoc blinded tumor FATSI analysis approach was considered more suitable for preliminary evaluation of this concept.

Methods
The Institutional Review Boards of Baptist Health South Florida and Western IRB approved this study (clinicaltrials.gov- NCT03274661). Patients (age > 18 years) with metastatic or recurrent solid malignancy who had progressed on first line standard of care treatment or for whom defined standard of care does not exist, and for whom there was not an FDA approved indication for pembrolizumab were offered participation in the trial.

Other eligibility requirements included progressive disease, measurable as per RECIST 1.1 criteria [21], and a lapse of 4 weeks from chemotherapy or radiation therapy. Patients needed an ECOG performance status ≤ 2 and normal organ and marrow function [absolute neutrophil count ≥ 1.5 x 10^9; platelets ≥ 100 x 10^9; hemoglobin ≥ 9 g/dL; serum creatinine and bilirubin ≤ 1.5 x upper limit of normal (ULN); AST/ALT ≤ 2.5 x ULN]. Exclusions requirements comprised pregnancy, active brain metastases or carcinomatous meningitis, active autoimmune disease that required systemic treatment within the past 2 years, uncontrolled concurrent illness, interstitial lung disease, diagnosis of immunodeficiency, receiving systemic steroid therapy or other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment, previous treatment with immune checkpoint inhibitors, active hepatitis or tuberculosis, or having received a live vaccine within 30 days. Patients with
known MMR-d cancer (i.e., with microsatellite instability, MSI-H) were excluded, as they could receive pembrolizumab as per standard of care.

**Treatment plan**

Patients who met eligibility criteria and signed informed consent received pembrolizumab 200 mg as a 30-minute intravenous infusion on day 1 of every 3 weeks cycles. Pembrolizumab was provided in 50 mg lyophilized powder for injection or 100 mg in 4 mL solution for injection from Merck & Co., Inc. (Kenilworth, NJ) as an investigational product. Withholding or discontinuation of pembrolizumab followed recommendations as per pembrolizumab (Keytruda®) prescribing information.

**Tumor imaging and assessment of disease response and toxicity**

Tumor assessments were performed by computer tomography (CT) or Magnetic Resonance Imaging (MRI). Measurable disease on scans obtained within 21 days of Fig. 1  
A. The Fanconi anemia pathway and formation of repair foci. Following DNA inter-strand crosslink damage, the FANCM-FAAP24-MHF1-MHF2 anchor complex recruits the FA core complex I, which functions to activate FANCD2 and FANCI by mono-ubiquitinating the proteins. The activated FANCD2 and FANCI heterodimers are subsequently transported to subnuclear foci (encircled), which in collaboration with additional genes result in homologous recombination DNA repair. B. The Fanconi Anemia triple stain immunofluorescence method (FATSI) was performed in Paraffin Embedded Solid Tumor slides stained with FATSI as observed with immunofluorescence microscope (400x). Left, FATSI positive (competent pathway); Right, FATSI negative (deficient pathway). DAPI (blue), Ki67 (red) and FANCD2 (green).
first dose of therapy was required. Scans were repeated every 2 cycles (6 weeks) and Immune-related Response Criteria (irRC) [22] were utilized for assessment of response to therapy. The Common Terminology Criteria for Adverse Events (CTCAE) version 5 was utilized for the grading of toxicities (https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference). Biomarker and correlative studies Archival paraffin embedded tumor tissue of patients participating in the trial was retrieved and sent to the Department of Pathology at Baptist Hospital of Miami. Tissue sections were cut to 4 μm and analyzed by FATSI staining, as previously described [19, 20] to assess for FA functional deficiency.

Given reported preclinical data associating certain microbiota with anti-tumor response to immune checkpoint inhibitors [23–25], we incorporated collection of stools samples in this trial from agreeing patients. For microbiome analyses, self-collection stools samples in Zymo tubes were solicited from consented patients at screening, week 7 and at the end of trial and kept refrigerated for batch analyses. Samples were shipped to Translational Genomics (TGen), Flagstaff, AZ, where DNA was extracted using the KingFisher MagMAX microbiome Ultra Nucleic Acid Isolation Kit (ThermoFisher). Bacterial DNA was quantitated by BactQuant assay [26]. Whole metagenome libraries were constructed using the KAPA Hyper Prep Kit. Libraries were sequenced on an Illumina NextSeq (2 × 150 bp) instrument.

Statistical analysis The primary endpoint was iORR. We expected that similar to MMR-d patients, the iORR will be ≥40% in patients with functional FA deficiency (FATSI-Negative) and <10% in patients without either HR repair deficiency or MMR deficiency. Based on our prior screening data, we anticipated that 25 to 30% of patients with solid tumors will be FA functionally deficient. We utilized a two-stage phase II design to detect an iORR of ≥20% in the whole population tested (which will include FATSI positive and negative patients) vs. the null hypothesis that the true iORR is ≤5%, representing a response by chance alone, or other infrequent unknown mechanism. H0: iORR ≤5% vs. H1: iORR ≥20% with 90% power and a Type I error rate of 10%. The alternative hypothesis of 20% iORR represented a weighted average of the anticipated 40% response in FATSI-negative patients and 10% response in FATSI-positive, assuming a 3 to 7 ratio of these patient groups. Interim analysis required that at least two of the first 20 evaluable patients enrolled had a response. If this occurred, 19 additional evaluable patients were to be accrued for a total of 39. Overall rejection criterion of the null hypothesis was observing at least four responses. The proposed two-stage design was chosen instead of the Simon Optimal or Minimax because it has a larger first stage enrollment and thus a higher expected number of FATSI-negative patients in the interim analysis. The 90% confidence interval estimates of iORR both overall and by FATSI status using the exact method (Clopper-Pearson) was calculated. We noted, however, that the planned study was small for a well-powered comparison given that we expected only 12 FATSI-negative patients. Instead, variation in iORR by FATSI status was assessed by considering the one-sided 95% lower confidence limit for the difference. Secondary endpoints included median iPFS and 20-week iPFS. In addition, we conducted a logistic regression analysis to find the association between FATSI status and iORR with adjustment for possible confounders, such as age, sex, race and number of prior treatment regimens. We used Firth method to account for sparse data bias.

The evaluation of the microbiome in stool samples was to derive clusters of patients with distinct microbiomes. Association to clinical endpoints was documented (but no formal statistics assessed) to serve as hypothesis generating for future studies.

Results Patients characteristics From November 2017 to November 2018, 41 (39 evaluable) patients were enrolled at Miami Cancer Institute clinics to fulfill the two-stage design. The characteristics of the enrolled patients are depicted on Table 1. The

| Table 1 Patients characteristics |
|----------------------------------|
| Enrolled patients, No. (evaluable)| 41 (39) |
| Median Age, Y (Range)            | 62 (36–83) |
| Sex                              | 34 F, 7 M |
| Race/ethnicity                   | 14 W, 3 AA, 1 A, 23 H |
| Median No. of prior regimens (range)| 2 (1–7) |
| Primary diagnosis                | Ovarian 11 |
|                                  | Endometrial 9 (2 carcino-sarcomas) |
|                                  | Pancreatic 2 |
|                                  | Colorectal 4 (1 neuro-endocrine) |
|                                  | Cervical 2 |
|                                  | Fallopian 2 |
|                                  | Vaginal 2 |
|                                  | Head and neck 2 (1 adenoid cystic), |
|                                  | Breast, esophagus, small-cell lung, small bowel, thymic, vulvar, Mullerian 1 each |

W White, AA African American, A Asian, H Hispanic/Latino
majority of patients [27] had gynecological malignancies, although patients with other malignancies with no FDA approval indications for pembrolizumab were also enrolled. Twenty-three (56%) of the patients enrolled were Hispanic/Latinos, reflecting the Miami-Dade County population demographics. The median number of prior systemic therapy regimens was two (range 1 to 7). The study was amended in February 2019 to allow an expansion cohort (11 additional patients) with MSI stable endometrial cancer (MS-EC).

Toxicities
Three hundred thirty-six cycles (range 1 to 35) of pembrolizumab were administered on trial. Pembrolizumab toxicities were consistent with previously published data (package insert). Grades 3 to 4 toxicities included nausea/vomiting (n=1); abdominal pain/bowel obstruction (n=2); dyspnea (n=1); hyperglycemia and fatigue (n=1 each). Two patients discontinued pembrolizumab due to intolerance or drug attributed toxicities (a patient with a fatal chronic obstructive pulmonary disease exacerbation during the second cycle, and a patient with grade 2 fatigue after the first cycle).

Antitumor activity
Imaging assessments were performed every 6 weeks. One patient was deemed not response-evaluable after a further review of baseline CT images demonstrated not clearly measurable disease. Another patient deteriorated rapidly due to tumor progression within a week of the first dose of treatment. Two antitumor responses occurred among the first 20 evaluable patients, so the study continued to the planned full accrual. Among 39 evaluable patients, response evaluation showed 2CR, 5PR, 11SD, and 21PD, (iORR 18%) (Table 2). The median intent-to-treat (n=41 patients) iPFS was 47 days (range: 26 to non-reached) and the 20-week iPFS was 32% (13/41).

Correlative studies
FATSI analysis was performed in a blinded fashion at the end of two-stage phase 2 trial accrual. Thirty-nine tissue sections specimens from 39 patients were successfully analyzed. Two patients had either an insufficient tumor specimen (n=1) or tissue sections with low Ki67 (n=1). Tumor specimens from 10 patients (26%) were FATSI negative. The tumor histology distribution of the FATSI negatives were as follows: 5 endometrial carcinomas, 1 ovarian papillary serous, 1 vaginal, 1 esophageal squamous, 1 colon adenocarcinoma and 1 adenoid cystic carcinoma of the mandible. The iORR of the FATSI negative patients was 50% (95% CI, 19 to 81%) (5 of the 7 responses, including 2 CRs of long durations [11 months and > 35 months so far]) and their disease control rate (CR/PR + SD) rate (2CR, 3PR, 2SD) was 70%.

Twenty-nine patients (74%) had FATSI positive tumors. The iORR of the FATSI positive patients was 7% (2/29) (95% CI, 0 to 16%), and their disease control rate (2 PR, 9 SD) was 38%. Median PFS were 202 days for patients with FATSI negative tumors and 43 for FATSI positive, and the 20-weeks PFS 70 and 21%, respectively. Despite the small numbers, the differences for iORR and 20-week iPFS were statistically significant (p=0.0022 and 0.0043, respectively). Table 2 depicts clinical endpoints according to FATSI tumor status.

Responding patients with FATSI negative tumors included two experiencing ≥1-year iPFS (CR and PR). They were previously treated (2–4 prior systemic regimens) patients with MS-EC. Two other MS-EC FATSI negative patients responded (CR and PR) and the fifth response occurred in ovarian papillary serous patient (PR). Responses in patients with FATSI positive tumors (both PRs) included one patient each with small bowel carcinoma and a cervical cancer patient. Of interest, the small bowel carcinoma patient who had a PR and went on to receive 35 cycles of pembrolizumab on trial, had his tissue re-evaluated for microsatellite instability. Results

### Table 2 Antitumor responses according to FATSI staining

| Best Response | All (n = 41) | FATSI + (n = 29) | FATSI Neg. (n = 10) | (ND/In, n = 2) |
|---------------|-------------|-----------------|---------------------|--------------|
| CR            | 2           | 0               | 2                   | 0            |
| PR            | 5           | 2               | 3                   | 0            |
| SD            | 11          | 9               | 2                   | 0            |
| PD            | 21          | 17              | 3                   | 1            |
| NE            | 2           | 1               | –                   | 1            |
| iORR          | 18%         | 7%              | 50%                 | 0%           |
| MiPFS (range) | 47 (26-NR) | 43 (26-NR) days | 202 (41-NR) days    | 39 (38–40) days |
| 20Weeks PFS   | 32%         | 21%             | 70%                 | 0%           |

*MiPFS Median progression free survival, *NR Not reached, *ND/In Not done/insufficient, NE Non-evaluable
showed MSI-H; thus, the patient went off trial and continued to receive pembrolizumab as per standard of care. The one other FATSI + tumor response (PR of 5 months duration) was a heavily pre-treated metastatic cervical cancer patient with high tumor mutation load as per next generation sequencing testing performed prior to enrollment.

Given the observed favorable clinical activity in enrolled MS-EC patients, 11 additional MS-EC patients, including a carcinosarcoma were enrolled. Response evaluation in this group showed 1 PR, 4SD and 6 PD. iPFS was 52 days (range 37 to NR). FATSI staining was performed in 10 of these patients; six were FATSI negative and four FATSI positive. The one antitumor response in this group occurred in one FATSI negative tumor patient and has persisted for more than a year (16 months progression-free at last assessment).

Figure 2 depicts iPFS according to FATSI status for the total population of 49 evaluable patients inclusive of the expansion cohort. iPFS had not yet been reached at the data cut off of 3 years in four patients (range 16 to 36 months) (Fig. 3). Despite the small numbers of patients, considerable differences can be appreciated, favoring patients with FA pathway repair dysfunction. Logistic regression analysis showed that the adjusted odds ratio of iORR was significantly lower in FATSI positive patients (iOR, 0.144, 95% CI: 0.023–0.899) (Table 1s).

Forty-four stool samples from 20 patients who provided sequential samples were sequenced. Quality metrics (fastqc/multiQC) showed ≥2.3 M reads per sample. Reads were classified using MetaPhlAn3 [27], and heatmaps were generated with Seaborn 0.11.1 and hclust2. Classified reads were examined for discriminating features, in group wise comparisons using LEfSe [28]. Three hundred sixty-two species were identified in the complete dataset. Taxonomy bar plots of the top 25 species (selected by abundance) are depicted in Fig. 4A. After Bray Curtis distance hierarchical clustering (heat map not shown), discriminating features of the microbiome profile from patients experiencing tumor progression versus patients with disease stability or response (PD [n = 5] vs SD [n = 10] or PR/CR [n = 5]) are shown in Fig. 4B.

Discussion

Immune checkpoint inhibition is an exciting therapeutic strategy that has revolutionized the way that solid tumor oncologists perceive cancer treatment, since a significant number of patients derive sizeable and sustained clinical benefit. Unfortunately, predictive biomarkers for clinical benefit are few and imperfect. MMR-d (per MLH1, MSH2, MSH6, and PMS2 immunohistochemistry (IHC) negative staining, or microsatellite instability assessment); PD-L1 expression; and tumor mutational burden (TMB) (when available) [1, 29] are the most common...
biomarkers being used in practice, with various degrees of success for patient selection. Alternative biomarkers that can identify additional patients most likely to benefit from immune checkpoint inhibition are needed. The hypothesis motivating this trial is that in addition to MMR-d other major functional DNA repair deficiencies, if properly assessed, can distinguish these patients.

A limited number of genomic NGS based panel assays have been incorporated to the assessment of HR deficiency in patients with some solid tumors such as breast, ovarian and prostate. This is based on the understanding that HR repair deficiency not only can predispose patients to cancer development, but also makes them more likely to derive clinical benefits from DNA breaking cytotoxics and PARP inhibitors [5–7, 30–33]. A large number of cancer predisposition HR mutated genes are represented in the FA pathway [9–17]; however, some of these are not routinely evaluated. Moreover, FA genes can undergo epigenetic changes that renders them functionally inactive [34, 35]. The FATSI test evaluates FANCD2 foci formation in the nucleus of proliferating cells, assessing endpoint functionality of the pathway [18], with the capability of potentially identifying germline loss of heterozygosity, as well as sporadic and epigenetic events that render HR functionally ineffective. In our hands with over 700 patients tested, 15–35% of solid tumors depending on their histological type are unable to form FANCD2 repair foci [19, 20]. It is unclear, whether there is overlap with other biomarkers, such as PD-L1 expression or TMB. Mismatch and HR repair are intrinsically linked and compensatory in normal and tumor cells. Thus, the prevailing thought is that overlap of both types of repair deficiency in the same tumor cells is unlikely [36].

The results of this study corroborate the clinical observation that some patients with advanced tumors for which there is not an FDA approved indication for single agent pembrolizumab can derive benefit from this agent. Close to a third of the patients treated had 20 weeks iPFS or longer. The FATSI analysis was performed successfully from archived tumor material in 49 patients, reflecting the simplicity of sampling preparation and analysis, as long as sufficient tumor tissue is available for slide preparation, akin to other IHC routinely performed tests. Because the test targets absence of FANCD2 nuclear
repair foci (FATSI negative) to detect FA repair deficiency, it is very important to exclude false negatives, especially those in low proliferating tumors. The incorporation of Ki67 as one of the immunofluorescence test antibodies to determine sufficient tumor cell proliferation largely eliminates this caveat.

Including the expansion cohort, 16 of 49 patients tested (33%) were FATSI negative. Their clinical outcomes were better (iORR 38%, miPFS 142 days, 20 W-iPFS 56%), and predominantly drove the clinical benefit with pembrolizumab observed for the whole group. The response rate for FATSI negative endometrial cancer patients was 45% (5/11, including 2 CRs). Although, it is a smaller sample size, it is tempting to put this response rate in perspective to the 13% (3/24) response rate for pembrolizumab for PDL-1 positive endometrial cancer patients in KENOTE 028 [37].

Table 3 depicts the available results for relevant biomarkers that could serve as potential confounding factors for the clinical benefit differences observed between FATSI negative and positive tumors. These include PDL-1 staining and TMB.

Multiple studies have reported that a favorable gut microbiome is associated with responses to ICIs, although with limited concordance among identified species [38–40]. Fecal microbiota transplant from responding melanoma patients to those resistant to ICIs resulted in reversal of resistance in some patients [41]. Significantly enriched taxa in responders included the Lachnospiraceae, Ruminococcaceae, Bifidobacteriaceae, and Coriobacteriaceae families. Similar to the cited studies, our sample size is small, although sequential sampling provided for both permanence and abundance. Of note, the patient with CR had Ruminococcus bromii in her stool samples. Our data, although limited, may serve to supplement larger datasets being created to continue to explore the intriguing observed interactions between immune response and the human gut bacterial commensalism.

Conclusions

The results of our study are encouraging. However, as noted on Table 3, PDL-1 and TMB measures were not correlatives required for the study and therefore did not obtain these for every patient due to clinical and insurance coverage practices. This introduces a significant confounding factor.

However, supporting the study rationale, our results suggest that beyond genomic signatures, FA pathway functional assessment should be taken into consideration, not only to enrich for patients most likely to derive
| Tumor Histology                          | FATSI | PD-L1 Score | TMB Score | Response |
|-----------------------------------------|-------|-------------|-----------|----------|
| Ovarian (Papillary Serous)             | Negative | N/A         | N/A       | PR       |
| Esophageal Squamous                    | Negative | N/A         | Intermediate | SD      |
| Endometrial                            | Negative | Negative| 9 muts/Mb  | CR       |
| Endometrial                            | Negative | Negative| 7 muts/Mb  | SD       |
| Endometrial                            | Negative | N/A         | N/A       | PR       |
| Adenoid Cystic Carcinoma              | Negative | N/A         | 7 muts/Mb  | PD       |
| Endometrium                            | Negative | N/A         | N/A       | CR       |
| Vaginal                                | Negative | N/A         | N/A       | PD       |
| Endometrium                            | Negative | N/A         | N/A       | PR       |
| Colon                                  | Negative | Negative| 9 muts/Mb  | PD       |
| Endometrial                            | Negative | Negative| 7 muts/Mb  | PD       |
| Endometrial                            | Negative | N/A         | 5 muts/Mb  | PD       |
| Endometrial                            | Negative | Negative| 14 muts/Mb | SD       |
| Endometrial                            | Negative | N/A         | N/A       | SD       |
| Endometrial                            | Negative | CPS > / = 1 | N/A       | PR       |
| Endometrial                            | Negative | Negative| 6 muts/Mb  | PD       |
| Colon                                  | Positive  | N/A         | N/A       | PD       |
| Thymic                                 | Positive  | N/A         | Low/3.5   | SD       |
| Ovarian                                | Positive  | N/A         | N/A       | PD       |
| Ovarian                                | Positive  | N/A         | N/A       | PD       |
| Fallopian Tube                         | Positive  | N/A         | N/A       | PD       |
| Cervical Squamous                      | Positive  | N/A         | High      | PR       |
| Pancreatic                             | Positive  | N/A         | N/A       | PD       |
| Endometrial Carcinosarcoma             | Positive  | Negative | Low/4     | PD       |
| Cervical Squamous                      | Positive  | N/A         | N/A       | SD       |
| Fallopian tube                         | Positive  | N/A         | N/A       | SD       |
| Pancreatic                             | Positive  | N/A         | Intermediate | PD    |
| Endometrial                            | Positive  | Negative | Low/6     | PD       |
| Ovarian (Serous)                       | Positive  | Negative | Low/4     | PD       |
| Ovarian                                | Positive  | N/A         | N/A       | SD       |
| Breast                                 | Positive  | N/A         | 7.9 muts/Mb | SD   |
| Ovarian (Serous)                       | Positive  | N/A         | 10 muts/Mb | PD       |
| Mullerian Remnant Papillary Serous     | Positive  | Negative| 6 muts/Mb  | SD       |
| Ovarian                                | Positive  | N/A         | N/A       | NE       |
| Neuroendocrine Colorectal              | Positive  | N/A         | N/A       | PD       |
| Ovarian                                | Positive  | N/A         | N/A       | PD       |
| Ovarian                                | Positive  | Negative| 1+, 2%     | N/A      | PD       |
| Tonsil                                 | Positive  | N/A         | N/A       | SD       |
| Ileum                                  | Positive  | N/A         | N/A       | PR       |
| Uterine Sarcoma                        | Positive  | Positive| 2+ 95%     | 4 muts/Mb | SD       |
| Vulvar                                 | Positive  | CPS < 1.0   | 4.2 muts/Mb | SD |
| Vaginal                                | Positive  | N/A         | N/A       | PD       |
| Ovarian                                | Positive  | 0%, Negative| 4 muts/Mb  | PD       |
| Endometrial                            | Positive  | N/A         | N/A       | PD       |
| Ovarian                                | Positive  | N/A         | N/A       | PD       |
| Endometrial                            | Positive  | N/A         | N/A       | SD       |
| Endometrial                            | Positive  | N/A         | N/A       | PD       |
| Endometrial Carcinosarcoma             | Positive  | CPS 3, 0% in older test | 4 muts/Mb | PD       |
| Endometrial Carcinosarcoma             | Positive  | Negative| 8 muts/Mb  | PD       |
benefit from PARP inhibition treatment, but also for treatment with ICIs. Additional tumor-specific studies evaluating FATS1 as an enrichment biomarker supporting treatment strategies featuring immune checkpoint inhibitors, alone or in combination with PARP inhibitors, are needed.

Abbreviations
- MSH-H: Microsatellite Instability High; HRR: Homologous-recombination-repair; FA: Fanconi Anemia; iORR: Immune Response Criteria response rate; PFS: Progression-free survival; MS-EC: MSI stable endometrial cancer; ICIs: Immune checkpoint inhibitors; F: Female; M: Male; CR: Complete Response; PR: Partial Response; SD: Stable Disease; PD: Progressive Disease; NE: Non-Evaluatable; MMR-d: Mismatch repair deficient; FDA: Food and Drug Administration; ULN: Upper limit of normal; CT: Computer tomography; MRI: Magnetic resonance imaging; CTCAE: Common Terminology Criteria for Adverse Events; Q: Quartile; IQR: Interquartile range; N: Number; NR: Not reached.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s40364-022-00386-0.

Acknowledgements
Special thanks to Gail Walker Office of Research Baptist Hospital of Miami for her help in the statistical design of the study. To Alfredo Pedro Alonso, Deborah Suarez and Kathleen Calienes at the Clinical Trials Office, Miami Cancer Institute and to Li Gao at Florida International University for their diligent work. Also, to Dr. Sarah Highlander at TGen, Staff for conducting the microbiome sequencing and analyses and for providing figures for the manuscript.

Authors' contributions
MVC: Principal Investigator of the trial. Conceptualized hypothesis and design and wrote protocol. Also accrued patients to the trial, managed treatment and toxicities. Wrote the manuscript. JPD: Co-Principal Investigator. Took over as Principal Investigator after departure from Dr. Villalona-Calero from Miami Cancer Institute. Contributed and accrued patients to the trial; managed treatment and toxicities and reviewed and edited final manuscript: WD. Performed and interpreted immunofluorescence-correlative tests in tissue in a blind fashion. Reviewed and edited manuscript: ZD. Oversaw the collection of archival tissue material, processing of specimens and delivery: ES. Contributed and accrued patients to the trial; managed treatment and toxicities and reviewed final manuscript: SA. Contributed and accrued patients to the trial; managed treatment and toxicities and reviewed final manuscript: TG. Contributed and accrued patients to the trial; managed treatment and toxicities and reviewed final manuscript: FA. Contributed and accrued patients to the trial; managed treatment and toxicities and reviewed final manuscript: SV. Contributed and accrued patients to the trial; managed treatment and toxicities and reviewed final manuscript: FD. Contributed and accrued patients to the trial; managed treatment and toxicities and reviewed final manuscript: SG. Contributed and accrued patients to the trial; managed treatment and toxicities and reviewed final manuscript: HV. Interpreted radiological scans, performed IRECIST measures and reviewed the final manuscript. All authors read and edited the manuscript. The author(s) read and approved the final manuscript.

Funding
Miguel A. Villalona-Calero and John P Diaz received financial and drug support to Miami Cancer Institute from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. The study funders had no role in the design of the study, the collection, analysis, or interpretation of the data, the writing of the manuscript, or the decision to submit the manuscript for publication.

Availability of data and materials
Collected and reported analyzed data exists at Miami Cancer Institute, Baptist Health South Florida, Clinical Research Department.

Declarations
Ethics approval and consent to participate
The Institutional Review Boards of Baptist Health South Florida and Western IRB approved this study (clinicaltrials.gov: NCT03274661, Sept 7, 2017 https://clinicaltrials.gov/ct2/show/NCT03274661?id=NCT03274661). All subjects signed written informed consent.

Consent for publication
No identifiable individual data is provided in the article.

Competing interests
The authors declare that they have no competing interests.

Author details
1 City of Hope National Medical Center, Duarte, California, USA. 2 Miami Cancer Institute at Baptist Health South Florida, Miami, Florida, USA. 3 Departments of Human & Molecular Genetics, Herbert Wertheim College of Medicine, at the Florida International University, Miami, Florida, USA. 4 Radiology Associates of South Florida, Miami, Florida, USA.

Received: 17 February 2022 Accepted: 18 May 2022 Published online: 03 June 2022

References
1. Le DT, Uram J, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.
2. Marcus L, Steven J, Lemery S, et al. FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;18:4070.
3. André T, Shiu K, Kim T, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207–18.
4. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7.
5. Farmer H, McCabe N, Lord CJ, et al. FDA approval summary: Pembrolizumab for the treatment of mismatch-repair-deficient advanced breast cancer. J Clin Oncol. 2019;37(18s):CRAS01 (suppl; abstr CRAS01).
6. Tutt A, Robson M, Garber J, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol. 2009;27(18s):CRAS01 (suppl; abstr CRAS01).
7. Fong P, Boss D, Yap T, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–34.
8. Audhe MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase-inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245–51.
9. Bagby GC Jr. Genetic basis of Fanconi anemia. Curr Opin Hematol. 2003;10(1):68–76.
10. D’Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer. 2003;3:23–34.
11. Reid S, Schindler D, Hänkenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007;39(2):162–4.
12. Xia B, Dorsman JC, Armeznian N, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet. 2007;39(2):159–61.
13. Smogorzewska A, Matsuo S, Vinciguerra P, et al. Identification of the FANCl protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell. 2007;129(2):289–301.
14. Kim Y, Lach FP, Desetty R, et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet. 2011;43:138–41.

15. Vaz F, Hanenberg H, Schuster B, et al. Mutation of the RADS1C gene in a Fanconi anemia-like disorder. Nat Genet. 2010;42:406–9.

16. Machida YJ, Machida Y, Chen Y, et al. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell. 2006;23(4):589–96.

17. Meetee AR, Zan Y, Wang W, et al. FANCL replaces BRCA1 as the likely ubiquitin ligase responsible for FANCD2 monoubiquitination. Cell Cycle. 2004;3(2):179–81.

18. Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell. 2000;7(2):249–62.

19. Duan W, Gao L, Zhao W, et al. Assessment of FANCD2 nuclear foci formation in paraffin embedded tumors: a potential patient enrichment strategy for treatment with DNA interstrand crosslink agents. Transl Res. 2013;161(3):156–64.

20. Villalona-Calero MA, Duan W, Zhao W, et al. Veliparib alone or in combination with Mitomycin C in patients with solid tumors with functional deficiency in homologous recombination repair. J Natl Cancer Inst. 2016 Feb;108(7).

21. Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Ca. 2009;45:228–47.

22. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–20.

23. Vézouz M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079–84.

24. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley JM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2018;359:104–8.

25. Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:10391.

26. Liu CM, Aziz M, Kachur S, et al. BactQuant: an enhanced broad-coverage bacterial quantitative real-time PCR assay. BMC Microbiol. 2012;12:56.

27. Beghini, et al. bioRxiv. 2020. https://doi.org/10.1101/2020.11.19.388223.

28. Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12:R60.

29. Rizvi NA, Hellmann M, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8.

30. Taniguchi T, Tischkowitz M, Ameziane N, et al. Homologous recombination deficiency in homologous recombination repair. J Natl Cancer Inst. 2018;359:97–103.

31. Hussain M, Mateo J, Fizazi K, et al. Survival with Olaparib in metastatic castration-resistant prostate Cancer. N Engl J Med. 2020;383(24):2345–57.

32. Eikesdal H, Yndestad S, Elzawahry A, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol. 2021;32(2):240–9.

33. Telli M, Timms K, Reid J, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple negative breast cancer. Clin Cancer Res. 2021;26(12):3764–73.

34. Wang Z, Li M, Lu S, et al. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol Ther. 2000;5(3):256–60.

35. Poh W, Dilley R, Moliterno A, et al. BRCA1 promoter methylation is linked to defective homologous recombination repair and elevated miR-153 to disrupt myeloid differentiation in myeloid malignancies. Clin Cancer Res. 2019;25(8):2513–22.

36. St ults DM, Kileen MW, Shelton BJ, et al. Recombination phenotypes of the NCI-60 collection of human cancer cells. BMC Mol Biol. 2011;12:23.

37. Ott P, Bang Y, Berton-Rigaud D, et al. Safety and antitumor activity of Pembrolizumab in advanced programmed death ligand 1-positive endometrial Cancer: results from the KEYNOTE-028 study. J Clin Oncol. 2017;35:2535–41.

38. Routy B, Le Chatelier E, Derose L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–7.

39. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:104–8.

40. Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:97–103.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.